Research graph
References from Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the context of the Chilean health care system. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 · External reference
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
10.1016/j.mayocp.2019.01.013 · 2019 · External reference
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 · External reference
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
10.1200/jco.2009.26.2543 · 2010 · External reference
Unresolved reference
2015 · External reference
Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes
10.1007/s12325-019-0876-4 · 2019 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
10.1016/j.jval.2013.08.2291 · 2014 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
2020 · External reference
Unresolved reference
2022 · External reference
Concurrent chemoradiotherapy for stage III non-small cell lung cancer: correct clinical management as the basis to move beyond
10.21037/atm.2018.10.38 · 2018 · External reference
A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients
10.1016/j.athoracsur.2017.05.071 · 2017 · External reference
Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study
10.1016/j.jtho.2021.05.003 · 2021 · External reference
Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec
10.3747/co.27.6241 · 2020 · External reference
Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer—Cross-Sectional Study of Eligibility and Administration Rates
10.3389/fonc.2020.586449 · 2020 · External reference
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
10.1200/jco.21.01308 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Private health insurance in Germany and Chile: two stories of co-existence, segmentation and conflict
10.1186/s12939-018-0831-z · 2018 · External reference
Increasing incidence of rotator cuff surgery: A nationwide registry study in Chile
10.1186/s12891-021-04938-7 · 2021 · External reference
Describing out-of-pocket health payments in Chile: a look at two health care systems
2013 · External reference
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System
10.1001/jamaoncol.2018.5449 · 2019 · External reference
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis
10.1016/j.lungcan.2020.05.011 · 2020 · External reference
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective
10.6004/jnccn.2020.7621 · 2021 · External reference
Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis
10.1080/14737167.2022.1993062 · 2022 · External reference
Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective
10.1007/s41669-021-00301-7 · 2022 · External reference
Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer
10.1111/1759-7714.14531 · 2022 · External reference
Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service
10.1016/j.clinthera.2020.03.012 · 2020 · External reference
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
10.1016/j.annonc.2020.01.007 · 2020 · External reference
Unresolved reference
2018 · External reference
